Chuyển giao T tế bào đồng dạng được chuyển gen với thụ thể kháng nguyên tổng hợp nhận diện CD19 chuột có thể tiêu diệt lymphoma và tế bào B bình thường

Sadelain, 2009, The promise and potential pitfalls of chimeric antigen receptors., Curr Opin Immunol, 21, 215, 10.1016/j.coi.2009.02.009 Kershaw, 2005, Supernatural T cells: genetic modification of T cells for cancer therapy., Nat Rev Immunol, 5, 928, 10.1038/nri1729 Rossig, 2006, Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors., J Immunother, 29, 21, 10.1097/01.cji.0000175492.28723.d6 Loskog, 2006, Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells [see comment]., Leukemia, 20, 1819, 10.1038/sj.leu.2404366 Lamers, 2007, Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo., Cancer Immunol Immunother, 56, 1875, 10.1007/s00262-007-0330-3 Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo., Mol Ther, 17, 1453, 10.1038/mt.2009.83 Singh, 2008, Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system., Cancer Res, 68, 2961, 10.1158/0008-5472.CAN-07-5600 Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells [see comment]., Blood, 112, 2261, 10.1182/blood-2007-12-128843 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma [see comment]., Nat Med, 14, 1264, 10.1038/nm.1882 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer., Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 Cheadle, 2010, Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells., J Immunol, 184, 1885, 10.4049/jimmunol.0901440 Nadler, 1983, B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes., J Immunol, 131, 244, 10.4049/jimmunol.131.1.244 Pontvert-Delucq, 1993, Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development., Blood, 82, 417, 10.1182/blood.V82.2.417.417 Haynes, 2001, Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma., J Immunol, 166, 182, 10.4049/jimmunol.166.1.182 Combadiere, 1996, Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T-cell apoptosis., J Exp Med, 183, 2109, 10.1084/jem.183.5.2109 Zhao, 2009, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity., J Immunol, 183, 5563, 10.4049/jimmunol.0900447 Brady, 2006, Rapid specific amplification of rat antibody cDNA from nine hybridomas in the presence of myeloma light chains., J Immunol Methods, 315, 61, 10.1016/j.jim.2006.07.002 Huston, 1988, Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli., Proc Natl Acad Sci U S A, 85, 5879, 10.1073/pnas.85.16.5879 Nguyen, 2003, Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function., Blood, 102, 4320, 10.1182/blood-2003-04-1255 Hughes, 2005, Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions., Hum Gene Ther, 16, 457, 10.1089/hum.2005.16.457 Gross, 1989, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity., Proc Natl Acad Sci U S A, 86, 10024, 10.1073/pnas.86.24.10024 Campbell, 1988, Immunotherapy of established murine B cell lymphoma: combination of idiotype immunization and cyclophosphamide., J Immunol, 141, 3227, 10.4049/jimmunol.141.9.3227 Antony, 2005, CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells., J Immunol, 174, 2591, 10.4049/jimmunol.174.5.2591 Kochenderfer, 2009, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor., J Immunother, 32, 689, 10.1097/CJI.0b013e3181ac6138 Yelton, 1981, Use of monoclonal antimouse immunoglobulin to detect mouse antibodies., Hybridoma, 1, 5, 10.1089/hyb.1.1981.1.5 Coffman, 1982, Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development., Immunol Rev, 69, 5, 10.1111/j.1600-065X.1983.tb00446.x Riddell, 1996, T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients., Nat Med, 2, 216, 10.1038/nm0296-216 Kochenderfer, 2006, Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses., J Immunol, 177, 8860, 10.4049/jimmunol.177.12.8860 Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells., J Exp Med, 202, 907, 10.1084/jem.20050732 Klebanoff, 2005, Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy [erratum appears in Trends Immunol. 2005;26(6):298]., Trends Immunol, 26, 111, 10.1016/j.it.2004.12.003 North, 1982, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells., J Exp Med, 155, 1063, 10.1084/jem.155.4.1063 Li, 2008, Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression., Cancer Gene Ther, 15, 382, 10.1038/cgt.2008.5 Tutt, 1998, Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors., J Immunol, 161, 3176, 10.4049/jimmunol.161.6.3176 Kowolik, 2006, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells., Cancer Res, 66, 10995, 10.1158/0008-5472.CAN-06-0160 Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [see comment]., Nat Med, 9, 279, 10.1038/nm827 Thomsen, 2008, Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies., Toxicology, 246, 18, 10.1016/j.tox.2007.10.017 Murphy, 1992, Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions., Eur J Immunol, 22, 1421, 10.1002/eji.1830220614 Murphy, 1996, The huPBL-SCID mouse as a means to examine human immune function in vivo., Semin Immunol, 8, 233, 10.1006/smim.1996.0029 Sakaguchi, 2004, Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses., Annu Rev Immunol, 22, 531, 10.1146/annurev.immunol.21.120601.141122 Hwu, 1995, In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes., Cancer Res, 55, 3369 Hand, 1993, Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies., Cancer Immunol Immunother, 36, 65, 10.1007/BF01754404 Morimoto, 2007, Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation., J Immunol, 178, 6849, 10.4049/jimmunol.178.11.6849 Higgins, 2002, Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen., J Immunol, 169, 3622, 10.4049/jimmunol.169.7.3622 Redmond, 2005, Peripheral tolerance of CD8 T lymphocytes., Immunity, 22, 275, 10.1016/j.immuni.2005.01.010 James, 2009, Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice., Blood, 114, 5454, 10.1182/blood-2009-08-232967 Pinthus, 2004, Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes., J Clin Invest, 114, 1774, 10.1172/JCI200422284 Kuster, 1990, Characterization and expression of the gene for the human Fc receptor gamma subunit: definition of a new gene family., J Biol Chem, 265, 6448, 10.1016/S0021-9258(19)39347-0 Dudley, 2008, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens., J Clin Oncol, 26, 5233, 10.1200/JCO.2008.16.5449 Quartier, 1999, Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients., J Pediatr, 134, 589, 10.1016/S0022-3476(99)70246-5 Kochenderfer, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 [published online ahead of print July 28, 2010]., Blood Smith, 2003, Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance., Oncogene, 22, 7359, 10.1038/sj.onc.1206939